NGF - The TrkA to successful pain treatment

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 279-287

  Kumar, Vinayak ^a   Mahal, Brandon A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti NGF antibodies; Chronic pain; Nerve growth factor; Neurotrophic factor; Nociceptor neurons

Indexed keywords

BIOLOGICAL MARKER; NAPROXEN; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PLACEBO; PROTEIN TYROSINE KINASE A; TANEZUMAB;

ADVERSE OUTCOME; ANALGESIA; CANCER PAIN; CHRONIC PAIN; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; HYPESTHESIA; KNEE PAIN; LOW BACK PAIN; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; NONHUMAN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PAIN THRESHOLD; PARESTHESIA; PELVIS PAIN SYNDROME; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RESPIRATORY TRACT INFECTION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 84874955155     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S33408     Document Type: Review

References (57)

1. Hefti FF, Rosenthal A, Walicke PA, et al. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci. 2006;27(2):85-91.
2. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. Sep 2001;413(6852):203-210.
3. Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? Bio Drugs. 2008;22(6):349-359.
4. Woodcock J. A difficult balance-pain management, drug safety, and the FDA. N Engl J Med. 2009;361(22):2105-2107.
5. Cohen S. Origins of growth factors: NGF and EGF. Ann N Y Acad Sci. 2004;1038:98-102.
6. Tuszynski MH. Nerve growth factor gene delivery: animal models to clinical trials. Dev Neurobiol. 2007;67(9):1204-1215.
7. Varon S, Conner JM. Nerve growth factor in CNS repair. J Neurotrauma. 1994;11(5):473-486.
8. Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716-1721.
9. Fiore M, Chaldakov GN, Aloe L. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev Neurosci. 2009;20(2):133-145.
10. Zhu W, Galoyan SM, Petruska JC, Oxford GS, Mendell LM. A developmental switch in acute sensitization of small dorsal root ganglion (DRG) neurons to capsaicin or noxious heating by NGF. J Neurophysiol. 2004;92(5):3148-3152.
11. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72:609-642.
12. Holtzman DM, Kilbridge J, Li Y, et al. TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons. J Neurosci. 1995;15(2):1567-1576.
13. Barrett GL. The p75 neurotrophin receptor and neuronal apoptosis. Prog Neurobiol. 2000;61(2):205-229.
14. Lad SP, Peterson DA, Bradshaw RA, Neet KE. Individual and combined effects of TrkA and p75NTR nerve growth factor receptors. A role for the high affinity receptor site. J Biol Chem. 2003;278(27):24808-24817.
15. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 2005;24(24): 4211-4223.
16. Zhu W, Oxford GS. Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1. Mol Cell Neurosci. Apr 2007;34(4):689-700.
17. McMahon SB. NGF as a mediator of inflammatory pain. Philosophical Transactions: Biological Sciences. 1996;351(1338):431-440.
18. Bonnington JK, McNaughton PA. Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor. J Physiol. 2003;551(Pt 2):433-446.
19. Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV. Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur J Neurosci. 1995;7(7):1484-1494.
20. Jimenez-Andrade JM, Martin CD, Koewler NJ, et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain. 2007;133(1-3):183-196.
21. Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005;115(1-2):128-141.
22. Kojima M, Ikeuchi T, Hatanaka H. Role of nerve growth factor in the expression of trkA mRNA in cultured embryonic rat basal forebrain cholinergic neurons. J Neurosci Res. 1995;42(6):775-783.
23. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217-1281.
24. Koltzenburg M, Bennett DL, Shelton DL, McMahon SB. Neutralization of endogenous NGF prevents the sensitization of nociceptors supplying inflamed skin. Eur J Neurosci. 1999;11(5):1698-1704.
25. McMahon SB, Bennett DL, Priestley JV, Shelton DL. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med. 1995;1(8):774-780.
26. McNamee KE, Burleigh A, Gompels LL, et al. Treatment of murine osteoarthritis with TrkAd5reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain. 2010;149(2):386-392.
27. Capsoni S, Covaceuszach S, Marinelli S, et al. Taking pain out of NGF: a "painless" NGF mutant, linked to hereditary sensory autonomic neuropathy type V, with full neurotrophic activity. PLoS One. 2011;6(2):e17321.
28. Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet. 1996;13(4):485-488.
29. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int. 2009;104(10):1476-1481.
30. Ochodnický P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011;30(7):1227-1241.
31. Raychaudhuri SK, Raychaudhuri SP. NGF and its receptor system: a new dimension in the pathogenesis of psoriasis and psoriatic arthritis. Ann N Y Acad Sci. 2009;1173:470-477.
32. Watanabe T, Inoue M, Sasaki K, et al. Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. BJU Int. 2011;108(2):248-251.
33. Kuo HC, Liu HT, Chancellor MB. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn. 2010;29(3):482-487.
34. Bloom AP, Jimenez-Andrade JM, Taylor RN, et al. Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. J Pain. 2011;12(6):698-711.
35. Jimenez-Andrade JM, Bloom AP, Stake JI, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci. 2010;30(44):14649-14656.
36. Evans L, Andrew D, Robinson P, Boissonade F, Loescher A. Increased cutaneous NGF and CGRP-labelled trkA-positive intra-epidermal nerve fibres in rat diabetic skin. Neurosci Lett. 2012;506(1):59-63.
37. Jimenez-Andrade JM, Ghilardi JR, Castañeda-Corral G, Kuskowski MA, Mantyh PW. Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain. 2011;152(11):2564-2574.
38. Shelton DL, Zeller J, Ho WH, Pons J, Rosenthal A. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain. 2005;116(1-2):8-16.
39. Abdiche Y, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Science. 2008;17(8):1326-1335.
40. Mantyh P, Tive L, Shelton D. Tanezumab, a humanized anti-nerve growth factor antibody for the treatment of pain. The Journal of Pain: Official Journal of the American Pain Society. 2009;10(4):S44.
41. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther. 2010;12(1):94-106.
42. Ekman E, Gimbel J, Bello A, et al. Efficacy and safety of intravenous tanezumab in osteoarthritis hip and knee pain: comparison to placebo and naproxen in two phase III studies (NCT00830063 and NCT00863304). The Journal of Pain: Official Journal of the American Pain Society. 2011;12(4):P55.
43. Haddley K. Tanezumab. Anti-NGF monoclonal antibody, Treatment of pain, Treatment of osteoarthritis. Drugs of the Future. 2010;35(5):373-378.
44. Zorbas M, Hurst S, Shelton D, Evans M, Finco D, Butt M. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol. 2011;59(2):334-342.
45. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521-1531.
46. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis and Cartilage/OARS, Osteoarthritis Research Society. 2011;19(12):1405-1412.
47. Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. 2011;19(6):639-646.
48. Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 2011;152(10): 2248-2258.
49. Pfizer. An efficacy and safety study of tanezumab for the treatment of pain associated with chronic abacterial prostatitis. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2009 [updated March 14, 2011]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00826514?term=NCT00826514&rank=1. NLM identifier: NCT00826514. Accessed April 15, 2012.
50. Nickel JC, Atkinson G, Krieger J, et al. Tanezumab therapy for chronic prostatitis/chronic pelvic pain syndrome (cp/cpps): preliminary assessment of efficacy and safety in a randomized controlled trial. The Journal of Urology. 2011;185(4):e573-e574.
51. Strauss AC, Dimitrakov JD. New treatments for chronic prostatitis/chronic pelvic pain syndrome. Nat Rev Urol. 2010;7(3):127-135.
52. Wood JN. Nerve growth factor and pain. N Engl J Med. Oct 2010; 363(16):1572-1573.
53. Pfizer. Safety and efficacy of tanezumab in patients with chronic pancreatitis. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated April 13, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01146561?term=NCT01146561&rank=1. NLM identifier: NCT01146561. Accessed April 15, 2012.
54. Allsop SA, Erstad DJ, Brook K, Bhai SF, Cohen JM, Dimitrakoff JD. The DABBEC Phenotyping System: towards a mechanistic understanding of CP/CPPS. Nat Rev Urol. 2011;8(2):107-113.
55. Mahal BA, Cohen JM, Allsop SA, et al. The role of phenotyping in chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2011; 12(4):297-303.
56. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. 1968;5(5):492-518.
57. Stamey TA. Prostatitis. J R Soc Med. 1981;74(1):22-40.